Editas Medicine: CRISPR Gene Editing Leader
November 11, 2020 at 09:35 AM EST
Editas is focused on the CRISPR gene-editing technology, which promises solutions to hereditary and chronic diseases. An exciting story, but is it investable?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|